Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Retained Earnings (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Retained Earnings for 10 consecutive years, with -$1.4 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 3589643.59% to -$1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 billion through Dec 2025, down 3589643.59% year-over-year, with the annual reading at -$1.4 billion for FY2025, 3589643.59% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.4 billion at Rhythm Pharmaceuticals, down from -$1.3 billion in the prior quarter.
  • The five-year high for Retained Earnings was $134000.0 in Q4 2023, with the low at -$1.4 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$404.0 million, with a median of -$616500.0 recorded in 2022.
  • The sharpest move saw Retained Earnings surged 245.65% in 2023, then crashed 3589643.59% in 2025.
  • Over 5 years, Retained Earnings stood at -$1000.0 in 2021, then tumbled by 9100.0% to -$92000.0 in 2022, then soared by 245.65% to $134000.0 in 2023, then tumbled by 129.1% to -$39000.0 in 2024, then plummeted by 3589643.59% to -$1.4 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.4 billion, -$1.3 billion, and -$1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.